PDS Biotechnology Corp (PDSB) has a current Price-to-Book (P/B) ratio of 4.20. Compared to its 3-year average P/B ratio of 4.14, the current P/B ratio is approximately 1.57% higher. Relative to its 5-year average P/B ratio of 4.17, the current P/B ratio is about 0.87% higher. PDS Biotechnology Corp (PDSB) has a Forward Free Cash Flow (FCF) yield of approximately -70.81%. Compared to its 3-year average FCF yield of -36.40%, the current FCF yield is approximately 94.51% lower. Relative to its 5-year average FCF yield of -25.24%, the current FCF yield is about 180.49% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PDSB competitors is 338.48, providing a benchmark for relative valuation. PDS Biotechnology Corp Corp (PDSB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PDSB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PDSB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PDSB currently overvalued or undervalued?

What is PDS Biotechnology Corp (PDSB) fair value?

PDSB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of PDS Biotechnology Corp (PDSB) is between NaN to NaN according to relative valuation method.

How does PDSB's valuation metrics compare to the industry average?

The average P/S ratio for PDSB's competitors is 338.48, providing a benchmark for relative valuation. PDS Biotechnology Corp Corp (PDSB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for PDS Biotechnology Corp (PDSB) as of Mar 03 2026?

As of Mar 03 2026, PDS Biotechnology Corp (PDSB) has a P/B ratio of 4.20. This indicates that the market values PDSB at 4.20 times its book value.

What is the current FCF Yield for PDS Biotechnology Corp (PDSB) as of Mar 03 2026?

As of Mar 03 2026, PDS Biotechnology Corp (PDSB) has a FCF Yield of -70.81%. This means that for every dollar of PDS Biotechnology Corp's market capitalization, the company generates -70.81 cents in free cash flow.

What is the current Forward P/E ratio for PDS Biotechnology Corp (PDSB) as of Mar 03 2026?

As of Mar 03 2026, PDS Biotechnology Corp (PDSB) has a Forward P/E ratio of -1.14. This means the market is willing to pay $-1.14 for every dollar of PDS Biotechnology Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for PDS Biotechnology Corp (PDSB) as of Mar 03 2026?

As of Mar 03 2026, PDS Biotechnology Corp (PDSB) has a Forward P/S ratio of 0.00. This means the market is valuing PDSB at $0.00 for every dollar of expected revenue over the next 12 months.

PDSB Valuation